Replies to post #247920 on Biotech Values

[DewDiligence]

Rivus [private] said its main drug in development, HU6, showed in an early, eight-week "proof of concept" study to cause weight loss comparable to the GLP-1 drugs while sparing muscle mass and avoiding nausea.

That’s a tall order. Somewhat like developing an anticoagulant that doesn’t increase bleeding risk or an SSRI that doesn’t have sexual side effects.

Thanks for the post.